

# G Michael Felker

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5234545/g-michael-felker-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354  
papers

25,458  
citations

80  
h-index

151  
g-index

439  
ext. papers

31,217  
ext. citations

8.4  
avg, IF

6.79  
L-index

#	Paper	IF	Citations
354	Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1077-84	59.2	1182
353	Diuretic strategies in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 797-805	59.2	1012
352	Effect of nesiritide in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 32-43	59.2	930
351	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1268-77	27.4	762
350	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2013</b> , 381, 29-39	40	693
349	Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 40-7	15.1	630
348	Ultrafiltration in decompensated heart failure with cardiorenal syndrome. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2296-304	59.2	577
347	Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 538-43	3	531
346	Decision making in advanced heart failure: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2012</b> , 125, 1928-52	16.7	511
345	A standardized definition of ischemic cardiomyopathy for use in clinical research. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 210-8	15.1	418
344	Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 997-1003	15.1	401
343	Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. <i>Circulation</i> , <b>2005</b> , 111, 2454-60	16.7	376
342	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , <b>2009</b> , 373, 1429-39	40	334
341	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2314-24	59.2	331
340	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 500-8	27.4	327
339	Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 196-206	15.1	325
338	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2533-43	27.4	322

337	Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1071-8	15.1	301
336	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1178-86	4.0	275
335	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2017</b> , 135, e1054-e1091	16.7	274
334	Echocardiographic findings in fulminant and acute myocarditis. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 227-32	15.1	274
333	Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 230-8	3.3	272
332	Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. <i>American Heart Journal</i> , <b>2009</b> , 158, 422-30	4.9	261
331	Risk stratification after hospitalization for decompensated heart failure. <i>Journal of Cardiac Failure</i> , <b>2004</b> , 10, 460-6	3.3	257
330	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 170-7	12.3	247
329	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 713-720	27.4	236
328	Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. <i>Circulation: Heart Failure</i> , <b>2009</b> , 2, 56-62	7.6	216
327	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 1958-1966	27.4	201
326	Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 779-84	7.6	201
325	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1085-1095	27.4	199
324	Anemia as a risk factor and therapeutic target in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 959-66	15.1	192
323	Inotropic therapy for heart failure: an evidence-based approach. <i>American Heart Journal</i> , <b>2001</b> , 142, 393-401	4.0	192
322	Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 2533-42	27.4	178
321	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation</i> , <b>2015</b> , 131, 1763-71	16.7	173
320	Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 72-8	7.6	173

319	Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 129-36	12.3	170
318	Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 625-8	3	167
317	The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. <i>Medicine (United States)</i> , <b>1999</b> , 78, 270-83	1.8	166
316	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 105-116	59.2	164
315	Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 628-36	7.6	161
314	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2016</b> , 388, 2895-2903	40	158
313	Cardiohepatic interactions in heart failure: an overview and clinical implications. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2397-2405	15.1	157
312	Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , <b>2014</b> , 1, 110-145	3.7	153
311	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 741-8	7.6	147
310	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and	12.3	143
309	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1444-1455	15.1	142
308	The pathophysiology of acute heart failure--is it all about fluid accumulation?. <i>American Heart Journal</i> , <b>2008</b> , 155, 9-18	4.9	142
307	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. <i>Circulation</i> , <b>2018</b> , 137, 2016-2028	16.7	137
306	Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , <b>2014</b> , 35, 16-24	9.5	134
305	Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1964-1975	59.2	134
304	Clinical implications of chronic heart failure phenotypes defined by cluster analysis. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1765-74	15.1	132
303	The problem of decompensated heart failure: nomenclature, classification, and risk stratification. <i>American Heart Journal</i> , <b>2003</b> , 145, S18-25	4.9	128
302	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1764-1773	27.4	128

301	Myocarditis and long-term survival in peripartum cardiomyopathy. <i>American Heart Journal</i> , <b>2000</b> , 140, 785-91	4.9	127
300	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 314-25	7.6	120
299	Diuretics and ultrafiltration in acute decompensated heart failure. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 2145-53	15.1	116
298	Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. <i>Circulation</i> , <b>2002</b> , 105, 1663-8	16.7	115
297	Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 950-958	16.2	114
296	Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1399-1406	15.1	114
295	2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2207-31	15.1	112
294	Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 240-5	7.6	111
293	The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 9-16	7.9	110
292	Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. <i>Circulation</i> , <b>2006</b> , 114, 127-32	16.7	103
291	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5	6	101
290	Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 84-92	7.9	100
289	Inotropes in the management of acute heart failure. <i>Critical Care Medicine</i> , <b>2008</b> , 36, S106-11	1.4	99
288	Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 291-9	15.1	98
287	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1230-40	12.3	95
286	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1172-9	7.6	95
285	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 716-726	59.2	92
284	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 321-9	9	92

283	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 800-809	12.3	91
282	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 471-82	12.3	90
281	Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 457-65	7.9	84
280	End points for clinical trials in acute heart failure syndromes. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 2248-58	15.1	84
279	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	84
278	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 961-7	12.3	83
277	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1257-64	12.3	82
276	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004646	7.6	81
275	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 853-71	15.1	80
274	Novel biomarkers in chronic heart failure. <i>Nature Reviews Cardiology</i> , <b>2012</b> , 9, 347-59	14.8	80
273	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	79
272	Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 260-8	7.9	79
271	Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. <i>Journal of the National Cancer Institute</i> , <b>1992</b> , 84, 1926-31	9.7	78
270	Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002639	7.6	77
269	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1262-70	12.3	75
268	Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 97-107	7.9	75
267	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 182-9	3.3	74
266	Recurrence of cardiac sarcoidosis in a heart transplant recipient. <i>Journal of Heart and Lung Transplantation</i> , <b>2005</b> , 24, 1988-90	5.8	74

265	Anemia in patients with heart failure and preserved systolic function. <i>American Heart Journal</i> , <b>2006</b> , 151, 457-62	4.9	74
264	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1130-9	12.3	73
263	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , <b>2017</b> , 38, 2364-2373	9.5	72
262	Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 619-632	7.9	72
261	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1041-50	9.5	72
260	Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 176-82 <sup>2,3</sup>		72
259	B-type natriuretic peptide - a biomarker for all seasons?. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 718-20	59.2	72
258	Natriuretic peptides in the diagnosis and management of heart failure. <i>Cmaj</i> , <b>2006</b> , 175, 611-7	3.5	71
257	Role of Volume Redistribution in the Congestion of Heart Failure. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	67
256	The Valsalva maneuver: a bedside "biomarker" for heart failure. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 117-22	2.4	67
255	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1133-43	12.3	66
254	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 193-201	7.9	62
253	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 329-340	7.9	61
252	Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1178-1195	15.1	61
251	Outcomes with an alternate list strategy for heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2005</b> , 24, 1781-6	5.8	61
250	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 1-13	7.9	58
249	Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000399	6	58
248	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1001-1010	12.3	57

247	Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 169-74	3	57
246	Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. <i>Gene Therapy</i> , <b>2016</b> , 23, 313-9	4	56
245	Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 27-43	3.3	55
244	Charting a roadmap for heart failure biomarker studies. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 477-88	7.9	54
243	Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 30-39	7.9	54
242	A global rank end point for clinical trials in acute heart failure. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 643-6	7.6	54
241	Inflammatory biomarkers in heart failure. <i>Congestive Heart Failure</i> , <b>2006</b> , 12, 324-8		54
240	Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1993</b> , 32, 471-6	3.5	54
239	Design of the RELAXin in acute heart failure study. <i>American Heart Journal</i> , <b>2012</b> , 163, 149-55.e1	4.9	53
238	Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 762-9	15.1	52
237	Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. <i>Annals of Thoracic Surgery</i> , <b>2011</b> , 92, 1414-8; discussion 1418-9	2.7	51
236	Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. <i>International Journal of Cardiology</i> , <b>2010</b> , 144, 175-9	3.2	51
235	The impact of arrhythmias in acute heart failure. <i>Journal of Cardiac Failure</i> , <b>2004</b> , 10, 279-84	3.3	51
234	Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1591-8	15.1	50
233	Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 724-734	7.9	49
232	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , <b>2013</b> , 34, 3128-36	9.5	48
231	Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 91-7	3.3	48
230	A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <i>Kidney International</i> , <b>2010</b> , 77, 239-46	9.9	48



229	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , <b>2009</b> , 14, 299-307	5	45
228	Clinical Implications of the New York Heart Association Classification. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e014240	6	45
227	Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	44
226	Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 74-81	3.3	44
225	Outpatient Worsening Heart Failure as a Target for Therapy: A Review. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 252-258.	6.2	43
224	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1104-13	12.3	43
223	Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , <b>2009</b> , 157, 957-70	4.9	43
222	Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 783-5	3	43
221	Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 380-8	7.9	42
220	Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 930-2	15.1	41
219	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <i>American Heart Journal</i> , <b>2014</b> , 167, 193-202.e1	4.9	40
218	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 591-599	7.9	40
217	Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 245-52	7.9	39
216	Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 594-600	5.8	39
215	Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. <i>American Heart Journal</i> , <b>2009</b> , 157, 926-32	4.9	39
214	Noncardiac comorbidities and acute heart failure patients. <i>Heart Failure Clinics</i> , <b>2013</b> , 9, 359-67, vii	3.3	37
213	Valvular heart disease in patients supported with left ventricular assist devices. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 215-22	7.6	37
212	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 319-26	3.3	37

211	Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 178-83	12.3	37
210	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	36
209	Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 777-84	3.3	36
208	A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 330-7	15.1	35
207	Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 663-72	6.1	35
206	Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. <i>American Heart Journal</i> , <b>2009</b> , 158, 965-71	4.9	35
205	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 26-32	3.3	34
204	Significance of hyponatremia in heart failure. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 17-26	5	34
203	Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 258-66	12.3	34
202	Diuretic management in heart failure. <i>Congestive Heart Failure</i> , <b>2010</b> , 16 Suppl 1, S68-72		34
201	Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 684-8	3.3	34
200	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 290-7	12.3	33
199	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 68-77	7.9	32
198	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 456-64	12.3	32
197	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , <b>2015</b> , 170, 298-305	4.9	32
196	Impact of left ventricular assist device bridging on posttransplant outcomes. <i>Annals of Thoracic Surgery</i> , <b>2009</b> , 88, 1457-61; discussion 1461	2.7	32
195	Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure--results from the relaxin for the treatment of patients with acute heart failure study. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 407-13	3.3	31
194	Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 40-49	7.9	31

193	A global ranking approach to end points in trials of mechanical circulatory support devices. <i>Journal of Cardiac Failure</i> , <b>2008</b> , 14, 368-72	3.3	31
192	Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. <i>Academic Emergency Medicine</i> , <b>2015</b> , 22, 94-112	3.4	30
191	Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. <i>American Heart Journal</i> , <b>2012</b> , 164, 862-8	4.9	30
190	Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?. <i>Fundamental and Clinical Pharmacology</i> , <b>2009</b> , 23, 633-9	3.1	30
189	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 304-314	12.3	30
188	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10, e003878	7.6	29
187	Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1540-1550	12.3	29
186	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1205-1217	15.1	28
185	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , <b>2018</b> , 39, 4255-4256	9.5	28
184	Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 347-358	7.9	27
183	Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 726-35	7.9	27
182	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011560	6	27
181	Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	26
180	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 757-764	16.2	26
179	Loop diuretics in heart failure. <i>Heart Failure Reviews</i> , <b>2012</b> , 17, 305-11	5	26
178	Mortality in primary and secondary myocarditis. <i>American Heart Journal</i> , <b>2004</b> , 147, 746-50	4.9	26
177	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 306-13	12.3	26
176	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFREF. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 158-168	7.9	26

175	Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1272-7	3	25
174	Ten-year experience with extended criteria cardiac transplantation. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1230-8	7.6	25
173	Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 361-8	7.6	25
172	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 97-108	15.1	25
171	Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 45-53	12.3	24
170	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2160-2171	12.3	24
169	Multi-marker strategies in heart failure: clinical and statistical approaches. <i>Heart Failure Reviews</i> , <b>2010</b> , 15, 343-9	5	23
168	The Impact of Worsening Heart Failure in the United States. <i>Heart Failure Clinics</i> , <b>2015</b> , 11, 603-14	3.3	22
167	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 170-181	6.1	22
166	Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 1087-94	7.6	22
165	N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. <i>American Heart Journal</i> , <b>2009</b> , 158, S37-44	4.9	22
164	Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 196-200	12.3	22
163	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005552	7.6	21
162	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 362-369	5.8	21
161	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , <b>2013</b> , 166, 629-35	4.9	21
160	United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1545-9	3	21
159	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. <i>PLoS ONE</i> , <b>2016</b> , 11, e0145881	3.7	21
158	Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 896-901	16.2	19

157	Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. <i>American Heart Journal</i> , <b>2019</b> , 211, 22-33	4.9	19
156	Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 997-1005	7.6	19
155	Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1684-1693	12.3	19
154	Rational use of inotropic therapy in heart failure. <i>Current Cardiology Reports</i> , <b>2001</b> , 3, 108-13	4.2	19
153	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 777-85	7.9	18
152	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 742-752	7.9	18
151	Advances in the surgical treatment of heart failure. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 249-53	2.1	18
150	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1031-1038	12.3	18
149	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 127-136	7.9	17
148	Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 429-440	7.9	16
147	Biomarker-based risk prediction in the community. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1342-1350	2.3	16
146	Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 573-9	3	16
145	Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry. <i>International Journal of Cardiology</i> , <b>2011</b> , 148, 17-22	3.2	16
144	Infectious complications in extended criteria heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2008</b> , 27, 1217-21	5.8	16
143	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 315-329	12.3	16
142	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2368-2378	15.1	16
141	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 177-186	15.1	16
140	Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 70-80	7.9	15

139	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1022-1031	12.3	14
138	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1097-1105	3.8	14
137	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 727-37	6.1	14
136	Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. <i>American Heart Journal</i> , <b>2010</b> , 160, 1142-8	4.9	14
135	Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006414	7.6	14
134	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 101-107	3.3	14
133	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 770-778	12.3	13
132	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006946	7.6	13
131	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1188-1198	3.7	13
130	Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. <i>Cardiology</i> , <b>2010</b> , 117, 190-6	1.6	13
129	Biomarker guided therapy for heart failure: focus on natriuretic peptides. <i>Heart Failure Reviews</i> , <b>2010</b> , 15, 351-70	5	13
128	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , <b>2020</b> , 220, 41-50	4.9	13
127	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2551-2562	15.1	13
126	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e010364	6	13
125	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 726-738	12.3	12
124	Mode of Death After Acute Heart Failure Hospitalization - A Clue to Possible Mechanisms. <i>Circulation Journal</i> , <b>2016</b> , 80, 17-23	2.9	12
123	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 738-42	3.3	12
122	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 280-292	6.1	12

121	Relationship between anemia and health care costs in heart failure. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, 843-9	3.3	12
120	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 684-92	12.3	12
119	Breastfeeding, Cellular Immune Activation, and Myocardial Recovery in Peripartum Cardiomyopathy. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 291-300	8.7	11
118	Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 684-685	59.2	11
117	Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 1059-64	3	11
116	Natriuretic Peptide-guided therapy for heart failure. <i>Circulation Journal</i> , <b>2011</b> , 75, 2031-7	2.9	11
115	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 745-53	6.1	11
114	Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 2003-2009	3	10
113	Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013047	6	10
112	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 943-953	7.9	10
111	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2018-2025	12.3	10
110	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 293-300	7.9	10
109	Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. <i>American Journal of Perinatology</i> , <b>2019</b> , 36, 476-483	3.3	10
108	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 1-12	7.9	10
107	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 98-105	3	9
106	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 486-493	2.7	9
105	Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 33-42	3.3	9
104	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1356.e21-1356.e28	3.8	9

103	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	9
102	Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 837-44	3.3	8
101	Anaemia and coronary artery disease severity in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 54-7	12.3	8
100	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007829	7.6	8
99	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1076-1084	12.3	8
98	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. <i>ASAIO Journal</i> , <b>2016</b> , 62, 505-12	3.6	8
97	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 314-323	27.4	8
96	Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. <i>North Carolina Medical Journal</i> , <b>2006</b> , 67, 110-5	0.6	8
95	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 709-16	7.6	7
94	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006827	7.6	7
93	Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	7
92	Fluid removal in acute heart failure: diuretics versus devices. <i>Current Opinion in Critical Care</i> , <b>2014</b> , 20, 478-83	3.5	7
91	How to use diuretics in heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2009</b> , 11, 426-32	2.1	7
90	Reduction in body weight but worsening renal function with late ultrafiltration for treatment of acute decompensated heart failure. <i>Cardiology</i> , <b>2012</b> , 123, 145-53	1.6	7
89	Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. <i>American Heart Journal</i> , <b>2001</b> , 142, 932-3	4.9	7
88	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , <b>2021</b> , 144, 180-182	16.7	7
87	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , <b>2016</b> , 23, 922-31	3.4	7
86	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 42-51	7.9	7



85	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 512-519	3.3	7
84	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , <b>2017</b> , 187, 62-69	4.9	6
83	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 703-711	3.3	6
82	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006758	7.6	6
81	Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 542-549	3.3	6
80	What's Next for Acute Heart Failure Research?. <i>Academic Emergency Medicine</i> , <b>2018</b> , 25, 85-93	3.4	6
79	Biomarkers as surrogate end points in heart failure trials. <i>Heart Failure Clinics</i> , <b>2011</b> , 7, 501-7	3.3	6
78	Mechanisms and Models in Heart Failure: A Translational Approach. <i>Circulation Research</i> , <b>2021</b> , 128, 1435-1450	4.5	6
77	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 47-55	7.9	6
76	The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 977-8	15.1	5
75	Approaches to decongestion in patients with acute decompensated heart failure. <i>Current Cardiology Reports</i> , <b>2013</b> , 15, 335	4.2	5
74	Dysphagia in the setting of left ventricular assist device hemolysis. <i>ASAIO Journal</i> , <b>2013</b> , 59, 322-3	3.6	5
73	Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need?. <i>Cardiology</i> , <b>2009</b> , 114, 75-82	1.6	5
72	A bridge for the 21st century in heart transplantation?. <i>American Heart Journal</i> , <b>2003</b> , 145, 198-9	4.9	5
71	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015752	6	5
70	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007814	7.6	5
69	Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 146-157	7.9	5
68	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 58-67	12.3	5

67	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 444-456	6.1	4
66	Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , <b>2017</b> , 63, 536-541	3.6	4
65	Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1703-1709	3	4
64	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1660-1666	3	4
63	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	4
62	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1561-1570	12.3	4
61	Management of the cardiorenal syndrome in acute heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2012</b> , 14, 342-55	2.1	4
60	Is there a rationale for antiplatelet therapy in acute heart failure?. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 869-76	7.6	4
59	Diagnosis and Management of Acute Heart Failure Syndromes <b>2012</b> , 517-542		4
58	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007456	7.6	4
57	Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial. <i>Circulation</i> , <b>2020</b> , 142, 1018-1020	16.7	4
56	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1147-1155	12.3	4
55	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1052-1056	12.3	4
54	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.. <i>JACC: Heart Failure</i> , <b>2021</b> ,	7.9	4
53	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 939-940	3.3	3
52	The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, S10-S11	3.3	3
51	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 913-921	7.9	3
50	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , <b>2020</b> , 220, 97-107	4.9	3

49	Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. <i>Circulation</i> , <b>2020</b> , 142, 790-798	16.7	3
48	Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008410	7.6	3
47	Probabilistic Rejudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , <b>2021</b> , 143, 2316-2318	16.7	3
46	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 670-676	3.3	3
45	Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 273-279	3.8	3
44	Dose Response of $\beta$ Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e002210	5.2	3
43	Inpatient Management of Heart Failure: Are We Shooting at the Right Target?. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 223-224	8	2
42	Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 608-9	3.3	2
41	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e012405	6	2
40	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , <b>2018</b> , 253, 91-96	3.2	2
39	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, S62-S63	3.3	2
38	Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trial. <i>Journal of Heart and Lung Transplantation</i> , <b>2006</b> , 25, 1164-6	5.8	2
37	Left ventricular assist devices as destination therapy for end-stage heart failure. <i>American Heart Journal</i> , <b>2004</b> , 148, 252-3	4.9	2
36	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2608-2616	3.7	2
35	Heart Failure as a Consequence of Ischemic Heart Disease <b>2020</b> , 254-268.e6		2
34	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 662-669	3.7	2
33	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , <b>2021</b> , 239, 110-119	4.9	2
32	Cardiac transplantation at Duke University Medical Center. <i>Clinical Transplants</i> , <b>2004</b> , 235-41		2

31	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1472-1476	12.3	1
30	Reply: applying cluster analysis to data of previously published chronic heart failure trials: systems biology and clinical phenotypes of heart failure syndrome. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1270-1271	15.1	1
29	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 727-732	3.3	1
28	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 618-27	3.3	1
27	Reply: predicting sudden cardiac death in heart failure. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 673	7.9	1
26	Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 111-3	5.8	1
25	Too much, too little, or just right?: untangling endogenous erythropoietin in heart failure. <i>Circulation</i> , <b>2010</b> , 121, 191-3	16.7	1
24	Etiology and overview of heart failure <b>2012</b> , 6-17		1
23	The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
22	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
21	Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006840	7.6	1
20	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e008007	7.6	1
19	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2021</b> , 5, 447-455	3.1	1
18	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019712	6	1
17	Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 161	8.7	1
16	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021276	6	1
15	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 266-275	7.9	1
14	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 890-903	7.9	0

13	Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 999-1008	7.9	o
12	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1359-1366	3.3	o
11	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , <b>2022</b> , CIRCHEARTFAILURE121008970	7.6	o
10	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024833	6	o
9	Reply: Mode of Death Prevention by Serelaxin. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 99	15.1	
8	Acute Decompensated Heart Failure <b>2018</b> , 233-240		
7	Acute Decompensated Heart Failure <b>2014</b> , 166-171		
6	Using genetic information to select treatment for patients with heart failure: has the time come?. <i>Personalized Medicine</i> , <b>2009</b> , 6, 385-392	2.2	
5	The African-American heart failure trial: a new look at old drugs. <i>Future Cardiology</i> , <b>2005</b> , 1, 311-3	1.3	
4	Clinical Trajectory of Patients with a Worsening Heart Failure Event and Reduced Ventricular Ejection Fraction.. <i>American Heart Journal</i> , <b>2021</b> , 245, 110-110	4.9	
3	Clinical Trial Design in Heart Failure <b>2010</b> , 570-593		
2	Acute Decompensated Heart Failure <b>2010</b> , 157-162		
1	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction <b>2020</b> , 520-548		